Back to Search
Start Over
Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of HCC.
- Source :
-
Hepatology (Baltimore, Md.) [Hepatology] 2024 Nov 01; Vol. 80 (5), pp. 1074-1086. Date of Electronic Publication: 2024 Feb 15. - Publication Year :
- 2024
-
Abstract
- Background and Aims: Cancer-associated fibroblasts (CAFs) play key roles in the tumor microenvironment. IgA contributes to inflammation and dismantling antitumor immunity in the human liver. In this study, we aimed to elucidate the effects of the IgA complex on CAFs in Pil Soo Sung the tumor microenvironment of HCC.<br />Approach and Results: CAF dynamics in HCC tumor microenvironment were analyzed through single-cell RNA sequencing of HCC samples. CAFs isolated from 50 HCC samples were treated with mock or serum-derived IgA dimers in vitro. Progression-free survival of patients with advanced HCC treated with atezolizumab and bevacizumab was significantly longer in those with low serum IgA levels ( p <0.05). Single-cell analysis showed that subcluster proportions in the CAF-fibroblast activation protein-α matrix were significantly increased in patients with high serum IgA levels. Flow cytometry revealed a significant increase in the mean fluorescence intensity of fibroblast activation protein in the CD68 + cells from patients with high serum IgA levels ( p <0.001). We confirmed CD71 (IgA receptor) expression in CAFs, and IgA-treated CAFs exhibited higher programmed death-ligand 1 expression levels than those in mock-treated CAFs ( p <0.05). Coculture with CAFs attenuated the cytotoxic function of activated CD8 + T cells. Interestingly, activated CD8 + T cells cocultured with IgA-treated CAFs exhibited increased programmed death-1 expression levels than those cocultured with mock-treated CAFs ( p <0.05).<br />Conclusions: Intrahepatic IgA induced polarization of HCC-CAFs into more malignant matrix phenotypes and attenuates cytotoxic T-cell function. Our study highlighted their potential roles in tumor progression and immune suppression.<br /> (Copyright © 2024 American Association for the Study of Liver Diseases.)
- Subjects :
- Humans
Male
Female
Bevacizumab therapeutic use
Bevacizumab pharmacology
Phenotype
Middle Aged
Antibodies, Monoclonal, Humanized therapeutic use
Antibodies, Monoclonal, Humanized pharmacology
Programmed Cell Death 1 Receptor metabolism
Progression-Free Survival
Tumor Microenvironment immunology
Liver Neoplasms pathology
Liver Neoplasms immunology
Carcinoma, Hepatocellular pathology
Carcinoma, Hepatocellular immunology
Cancer-Associated Fibroblasts metabolism
Cancer-Associated Fibroblasts pathology
Cancer-Associated Fibroblasts immunology
Immunoglobulin A metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1527-3350
- Volume :
- 80
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Hepatology (Baltimore, Md.)
- Publication Type :
- Academic Journal
- Accession number :
- 38466639
- Full Text :
- https://doi.org/10.1097/HEP.0000000000000772